Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Maintaining Hold on Envista Holdings Amid Financial Challenges and Uncertain Recovery
Envista Holdings: Sell Rating Justified by Poor Q2 Performance and Negative FY24 Guidance
Envista Holdings Price Target Cut to $19.00/Share From $22.00 by B of A Securities
Evercore ISI Group Maintains Outperform on Envista Holdings, Lowers Price Target to $18
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Envista Holdings (NVST) and Soleno Therapeutics (SLNO)
Envista Holdings (NVST) Receives a Hold From Piper Sandler
Envista Holdings Analyst Ratings
Envista Holdings: A Cautious Hold Amidst Transition and Anticipated Strategic Insights
UBS Adjusts Envista Price Target to $17 From $22, Maintains Neutral Rating
Envista Holdings Price Target Cut to $16.00/Share From $18.00 by Piper Sandler
Envista Holdings Analyst Ratings
Piper Sandler Maintains Neutral on Envista Holdings, Lowers Price Target to $16
Stifel Maintains Envista Holdings(NVST.US) With Buy Rating, Cuts Target Price to $18
Envista Holdings (NVST) Receives a Hold From Piper Sandler
Envista Holdings Price Target Cut to $17.00/Share From $19.00 by Baird
Envista Holdings Analyst Ratings
Baird Maintains Neutral on Envista Holdings, Lowers Price Target to $17
Baird Maintains Envista Holdings(NVST.US) With Hold Rating, Cuts Target Price to $17
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)